Back

Transcriptomic Immune-related Signature Predictive of Chemoradiotherapy Response in Anal Squamous Cell Carcinoma

Iseas, S.; Golubicki, M.; Lacunza, E.; Prost, D.; Bouchereau, S.; Lahaie, C.; Baba-Hamed, N.; Raymond, E.; Adam, J.; Abba, M. C.

2026-03-13 oncology
10.64898/2026.03.12.26348072 medRxiv
Show abstract

Anal squamous cell carcinoma (ASCC) is a rare malignancy associated with high-risk HPV, with rising incidence among younger adults. While immunotherapy has improved outcomes in metastatic ASCC, treatment for localized disease remains largely unchanged, with high recurrence rates. This study provides comprehensive exome and transcriptome profiling of 40 stage I-III non-metastatic ASCC patients treated with curative chemoradiotherapy (CRT) to identify predictors of treatment response and progression-free survival. Transcriptomic analysis revealed 350 differentially expressed genes between complete responders (CR) and non-complete responders (NCR) (p-value<0.01; FC>2). CR was associated with modulation of immune-related pathways, cytokine production, epidermis development, cell differentiation, and signaling pathways associated with TNFA/NFkB and epithelial to mesenchymal transition. Immune infiltrate analysis showed significant enrichment of CD8+ central memory T cells (p=0.008) in CR cases, correlating with increased tertiary lymphoid structure and improved overall (p=0.0026) and disease-free survival (p=0.0098). Exome-seq identified alterations in novel and known cancer driver genes without association to CRT response, despite high tumor mutational burden (TMB) was significantly associated with shorter overall (p=0.03) and disease-free survival (p=0.027) compared with low TMB cases. These findings highlight the potential of incorporating gene expression signatures (e.g., FDCSP, ALDOB, ADGRB1, SPINK7) alongside immune-related markers into clinical practice to enhance the prediction of treatment response and guide personalized therapies in ASCC. A robust and functionally active immune microenvironment, characterized by specific T and B cell populations and the presence of tertiary lymphoid structures, emerges as a hallmark of complete response and improved survival in ASCC patients undergoing chemoradiotherapy.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.3%
10.4%
2
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.1%
9.1%
3
Clinical Cancer Research
58 papers in training set
Top 0.1%
9.1%
4
Annals of Oncology
13 papers in training set
Top 0.1%
8.3%
5
Frontiers in Oncology
95 papers in training set
Top 0.6%
6.3%
6
Nature Communications
4913 papers in training set
Top 40%
3.6%
7
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.1%
3.6%
50% of probability mass above
8
Oncogene
76 papers in training set
Top 0.7%
2.6%
9
eLife
5422 papers in training set
Top 34%
2.3%
10
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.2%
2.1%
11
British Journal of Cancer
42 papers in training set
Top 0.7%
2.1%
12
BMC Cancer
52 papers in training set
Top 1%
1.9%
13
Scientific Reports
3102 papers in training set
Top 54%
1.9%
14
European Journal of Cancer
10 papers in training set
Top 0.1%
1.9%
15
JNCI Cancer Spectrum
10 papers in training set
Top 0.2%
1.9%
16
Cancer Letters
32 papers in training set
Top 0.2%
1.7%
17
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
18
Journal of Translational Medicine
46 papers in training set
Top 1.0%
1.7%
19
Cancer Medicine
24 papers in training set
Top 0.9%
1.5%
20
Frontiers in Immunology
586 papers in training set
Top 5%
1.3%
21
Molecular Oncology
50 papers in training set
Top 0.5%
1.3%
22
PLOS ONE
4510 papers in training set
Top 59%
1.3%
23
Cancer Cell
38 papers in training set
Top 1%
1.2%
24
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
1.2%
25
Theranostics
33 papers in training set
Top 1.0%
1.1%
26
npj Precision Oncology
48 papers in training set
Top 1.0%
0.9%
27
OncoImmunology
22 papers in training set
Top 0.3%
0.9%
28
Gastroenterology
40 papers in training set
Top 2%
0.8%
29
Frontiers in Bioinformatics
45 papers in training set
Top 1.0%
0.7%
30
The Journal of Pathology
22 papers in training set
Top 0.5%
0.7%